Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Myocarditis I: Introduction01:21

Myocarditis I: Introduction

71
Myocarditis is inflammation of the myocardium, which is the muscular layer of the heart.EtiologyMyocarditis has a diverse etiology, including a wide range of infectious and non-infectious causes:Infectious CausesViral: Common viruses include Coxsackie A and B, adenovirus, parvovirus B19, enteroviruses, and influenza A.Bacterial: Examples include infections caused by Streptococcus, Staphylococcus, and Mycoplasma species.Rickettsial: Infections like Rocky Mountain spotted fever can result in...
71
Cardiomyopathy IV: Restrictive Cardiomyopathy01:29

Cardiomyopathy IV: Restrictive Cardiomyopathy

116
Restrictive cardiomyopathy (RCM) is a rare heart muscle disease characterized by impaired ventricular filling due to stiffened ventricular walls, leading to significant diastolic dysfunction.EtiologyRestrictive cardiomyopathy can arise from both inherited and acquired diseases, many of which are systemic. It is categorized into four main types: infiltrative, storage, non-infiltrative, and endomyocardial diseases.Infiltrative diseases, such as amyloidosis, lead to RCM by depositing amyloid...
116
Cardiomyopathy II: Dilated Cardiomyopathy01:30

Cardiomyopathy II: Dilated Cardiomyopathy

77
Dilated cardiomyopathy, or DCM, is a progressive myocardial disorder characterized by ventricular chamber dilation and contractile dysfunction.EtiologyVarious factors can cause DCM, including hypertension and heavy alcohol intake, which contribute to the weakening and enlargement of the heart muscle. Viral infections, such as Coxsackievirus B, adenoviruses, and influenza, can lead to DCM by causing inflammation and damage to heart tissue. Certain chemotherapeutic agents, including daunorubicin,...
77
Cardiomyopathy III: Hypertrophic Cardiomyopathy01:29

Cardiomyopathy III: Hypertrophic Cardiomyopathy

94
Hypertrophic cardiomyopathy, or HCM, is an autosomal dominant genetic disorder characterized by asymmetric left ventricular hypertrophy without ventricular dilation. It is more common in men and is typically diagnosed in young, athletic adults.EtiologyHCM is primarily genetic and is caused by mutations in genes encoding sarcomeric proteins. Researchers have identified over 1400 mutations across at least 11 different genes. Among these, the most frequently occurring mutations are found in the...
94
Myocarditis III: Medical Management01:14

Myocarditis III: Medical Management

31
Myocarditis: Comprehensive Medical ManagementMyocarditis, the heart muscle inflammation, requires a comprehensive medical management strategy that addresses the underlying cause, provides supportive care, manages symptoms, and reduces cardiac workload.Infections and Autoimmune CausesAdminister appropriate antimicrobial therapy when an infectious agent causes myocarditis. For instance, penicillin treats infections caused by Group A Streptococcus. In cases where autoimmune processes are...
31
Cardiomyopathy I: Introduction and Classification01:25

Cardiomyopathy I: Introduction and Classification

127
Cardiomyopathy, or CMP, is a group of diseases affecting the myocardial structure, impairing its ability to pump blood effectively. This condition can lead to arrhythmias, heart failure, or sudden cardiac death.Cardiomyopathies are classified into primary and secondary categories:Primary Cardiomyopathy refers to conditions involving only the heart muscle that are often idiopathic (of unknown cause) or genetic. They primarily affect the myocardium without the involvement of other systemic...
127

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Real-world treatment patterns and outcomes in older patients with metastatic breast cancer: a multi-institutional retrospective cohort study.

Breast cancer research and treatment·2026
Same author

Impact of body weight on clinical outcomes in cancer patients with low-risk pulmonary embolism receiving rivaroxaban: Insights from the ONCO PE trial.

Thrombosis research·2026
Same author

An investigation to identify the factors for negative sentinel lymph node metastasis in early breast cancer cases.

Breast cancer (Tokyo, Japan)·2026
Same author

<i>MAML2</i>-Rearranged Hidradenoma of the Breast: Clinicopathologic and Molecular Analysis of Four Patients.

Case reports in pathology·2026
Same author

Acute esophageal mucosal injury during pembrolizumab treatment after a hypopharyngeal cancer patient's free jejunal autograft reconstruction, as an immune-related adverse event.

International cancer conference journal·2026
Same author

Clinical and virological impacts of human parvovirus B19 epidemics on fulminant myocarditis in childhood.

BMC pediatrics·2026

Related Experiment Video

Updated: Oct 19, 2025

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.9K

Myocardial dysfunction caused by abemaciclib: a case report.

Takuya Oyakawa1, Lina Inagaki2, Zhensheng Hua1

  • 1Department of Onco-Cardiology/Cardiovascular Medicine, The Cancer Institute Hospital of Japanese Foundation for Cancer Research, 3-8-31 Ariake, Koto-ku, Tokyo, 135-8550 Japan.

International Cancer Conference Journal
|September 27, 2021
PubMed
Summary

Abemaciclib can cause reversible heart failure in metastatic breast cancer patients. Early detection and treatment of abemaciclib-induced myocardial dysfunction are crucial for patient recovery.

Keywords:
AbemaciclibCDK4/6 inhibitorCardiac magnetic resonance imagingCardio-oncologyHeart failureMyocardial dysfunction

More Related Videos

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
09:16

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients

Published on: February 28, 2018

7.8K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

1.1K

Related Experiment Videos

Last Updated: Oct 19, 2025

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation
08:03

Hybrid Cell Analysis System to Assess Structural and Contractile Changes of Human iPSC-Derived Cardiomyocytes for Preclinical Cardiac Risk Evaluation

Published on: October 20, 2022

1.9K
Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients
09:16

Isolation and Characterization of Cardiac Mesenchymal Stromal Cells from Endomyocardial Bioptic Samples of Arrhythmogenic Cardiomyopathy Patients

Published on: February 28, 2018

7.8K
Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System
10:17

Real-Time Cardiac Mapping with a Noninvasive Imageless Electrocardiographic Imaging System

Published on: April 11, 2025

1.1K

Area of Science:

  • Cardiology
  • Oncology
  • Pharmacology

Background:

  • Metastatic breast cancer treatment often involves targeted therapies like abemaciclib.
  • Cardiotoxicity is a known, albeit uncommon, side effect of certain cancer therapeutics.
  • Monitoring for cardiac adverse events is essential during chemotherapy.

Observation:

  • A 68-year-old female with metastatic breast cancer developed heart failure symptoms 12 weeks after initiating abemaciclib and fulvestrant.
  • Clinical presentation included dyspnea, edema, weight gain, elevated cardiac biomarkers (BNP, troponin I), and increased cardiothoracic ratio.
  • Cardiac imaging revealed reduced left ventricular ejection fraction and myocardial late gadolinium enhancement on MRI.

Findings:

  • Abemaciclib was diagnosed as the cause of drug-induced myocardial dysfunction and heart failure.
  • Discontinuation of abemaciclib and initiation of heart failure medications (enalapril, furosemide) led to significant clinical and imaging improvement.
  • Cardiac function normalized within three months of treatment cessation and management.

Implications:

  • This case highlights the potential for abemaciclib to induce reversible cardiac dysfunction.
  • Prompt recognition and management of abemaciclib-induced cardiotoxicity can lead to favorable outcomes.
  • Clinicians should maintain a high index of suspicion for cardiac adverse events in patients receiving abemaciclib.